EAU 2017: Variation in the use of active surveillance for low-risk prostate cancer

London, England (UroToday.com) Despite active surveillance being a standard of care for low-volume, low-risk prostate cancer, its utilization remains low. As overtreatment of prostate cancer remains a significant concern, the underutilization of active surveillance needs to be identified and addressed. The authors of this study utilize the National Cancer Database (NCDB), a large United States cancer database, to evaluate the influence of institutional factors associated with receipt of active surveillance.

EAU 2017: Metastases and death after 15 year of follow-up in men with screen-detected low-risk prostate cancer treated with protocol based active surveillance, radical prostatectomy or radiotherapy

London, England (UroToday.com) At this afternoon’s EAU 2017 Active Surveillance for Low-Risk Prostate Cancer poster session, Dr. Roobol and colleagues from The Netherlands presented their research on 15-year follow-up for men receiving active surveillance (AS), radical prostatectomy (RP), or radiotherapy (RT), specifically assessing metastases and death outcomes.

EAU 2017: MRI as a follow up tool in active surveillance – results from an MRI-defined active surveillance cohort (387 men, median 5 year follow up)

London, England (UroToday.com) At this afternoon’s EAU 2017 Active Surveillance for Low-Risk Prostate Cancer poster session, Dr. Retter and colleagues from London, UK presented their research assessing the utilization of MRI in active surveillance (AS) algorithms.

EAU 2017: Risk-based selection for active surveillance: Results of the Movember Foundation’s Global Action Plan prostate cancer active surveillance (GAP3) initiative

London, England (UroToday.com) Dr. Nieboer and colleagues from The Netherlands presented their research assessing risk-based selection for active surveillance (AS). The authors objective was to identify predictors of disease progression at 1 or 4 years in an attempt to support risk-based patient selection.

EAU 2017: Variation in the use of active surveillance for low-risk prostate cancer

London, England (UroToday.com) At this afternoon’s EAU 2017 Active Surveillance for Low-Risk Prostate Cancer poster session, Dr. Loppenberg and colleagues from Boston, USA presented their research regarding variation in the use of active surveillance (AS) for low risk prostate cancer. With recent reports suggesting an uptake worldwide in AS for low risk prostate cancer, further evaluating institutional factors associated with receipt of AS is important.

EAU 2017: State-of-the-art Lecture: EAU Guidelines on mCRPC – An Update

London, England (UroToday.com) Dr. Philip Cornford delivered the highly anticipated update of the EAU Guidelines for metastatic castration-resistant prostate cancer (mCPRC) [1].  Dr. Cornford reviewed the definition of CRPC, including a castrate level of serum testosterone <50 ng/mL plus either (i) biochemical progression – three consecutive rises of PSA, resulting in two 50% increases above the nadir value, with PSA >2 ng/mL, or (ii) radiological progression – the appearance of two or more bone lesions on bone scan or enlargement of a soft tissue lesion based on RECIST criteria.

EAU 2017: Is There a Role for Local Treatment of Oligometastatic Disease? No

London, England (UroToday.com) The highly anticipated thematic session “Controversies in Metastatic Prostate Cancer” this morning at the EAU 2017’s annual congress was a ‘standing room only’ event. Professor Bertrand Tombal started the proceedings by highlighting that there truly is no current evidence regarding the role for local treatment of oligometastatic disease.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe